登录 | 注册    微信公众号  
搜索
 > 【CD39】

CD39信息

英文名称:Ectonucleoside triphosphate diphosphohydrolase 1
中文名称:外核苷三磷酸二磷酸水解酶-1
靶点别称:CD39 Antigen,CD39,EC 3.6.1.5,NTPDase-1,NTPDase 1,ATPDase,SPG64,EC:3.6.1.5,Ecto-ATPase 1,Lymphoid cell activation antigen,ENTPD1,Ectonucleoside Triphosphate Diphosphohydrolase 1,Ecto-ATPDase 1,Ecto-Apyrase,Ecto-ATP diphosphohydrolase 1,EC 3.6.1
上市药物数量:0
临床药物数量:5
最高研发阶段:临床二期

CD39产品列表

 
评论(3)
CD9-C52H3|Cynomolgus CD39 / ENTPD1 Protein, His Tag (MALS verified) (active enzyme)
  1. 180XXXXXXX9
  2. 1人赞
  3. Cynomolgus CD39用于免疫血清效价检测及后续抗体筛选,前期检测血清效价结果较为理想,期待后续的抗体筛选取得好结果
  4. 2022-01-10
CD9-H52H4|Human CD39 / ENTPD1 Protein, His Tag (active enzyme)
  1. 180XXXXXXX9
  2. 2人赞
  3. 购买CD39用于动物免疫、后续抗体筛选和检测。抗原蛋白通过检测,纯度、活性方面都非常好,目前已准备免疫,期待获得良好的免疫效果。
  4. 2021-12-09
CD9-H52H4|Human CD39 / ENTPD1 Protein, His Tag (active enzyme)
  1. 136XXXXXXX6
  2. 14人赞
  3. 购买蛋白用于测试CD39封闭性抗体封闭CD39水解ATP的功能实验。通过系列梯度CD39抗体与一定浓度的CD39(0.5ug/ml)孵育,再加入50uM ATP,用CTG检测,得到很好的曲线。证明该蛋白具有很好的ATP酶水解功能。
  4. 2019-11-11
 

CD39 分子别名

CD39,ENTPD1,NTPDase 1,Entpd1,Ecto-ATPDase 1,Ecto-ATPase 1

CD39 分子背景

CD39 is also known as Ectonucleoside triphosphate diphosphohydrolase 1, ENTPD1, NTPDase 1, Ecto-ATPDase 1, in the nervous system, could hydrolyze ATP and other nucleotides to regulate purinergic neurotransmission. Could also be implicated in the prevention of platelet aggregation by hydrolyzing platelet-activating ADP to AMP. Hydrolyzes ATP and ADP equally well. NTPDase-1 was originally described as CD39, a B lymphocyte cell surface marker, but it is also present on the surface of natural killer cells, T cells, and some endothelial cells.Regulatory T cells(Tregs) mediate immunosuppression through multiple, non-redundant, cell-contact dependent and independent mechanisms, a growing body of evidence suggests an important role for the CD39-CD73-adenosine pathway. CD39 ectonucleotidase is the rate-limiting enzyme of a cascade leading to the generation of suppressive adenosine that alters CD4 and CD8 T cell and natural killer cell antitumor activities.

CD39 前沿进展

CD39临床药物信息

英文名称 研发代码 研发阶段 公司 适应症 临床试验
IPH-5201 IPH-5201 临床一期 Inserm, Orega Biotech 实体瘤 详情
JS-019 JS-019 临床一期 北京恩瑞尼生物科技股份有限公司 肿瘤 详情
SRF-617 SRF-617 临床二期 Surface Oncology 实体瘤, 前列腺癌 详情
TTX-030 TTX-030 临床一期 Tizona Therapeutics, 艾伯维 实体瘤, 淋巴瘤 详情
ES-002 ES-002 临床一期 科望(上海)生物医药科技有限公司 实体瘤, 肿瘤 详情
ES-002023(Elpiscience Biopharma) 临床一期 科望(上海)生物医药科技有限公司 实体瘤 详情
PUR-001 PUR-001 临床一期 Purinomia Biotech Inc 实体瘤 详情

消息提示

请输入您的联系方式,再点击提交!

确定